

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRITreporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. BMJ. 2013;346:e7586

	Reporting Item	Page Number
Administrative information		
Title	#1	1
Trial registration	#2a ClinicalTrials.gov: NCT05526053.	4
Trial registration: data set	#2b August 2023	4
Protocol version	#3 Version 3	3
Funding	#4 Fundación Española del Enfermo Crítico (10.000€)	16
Roles and responsibilities: contributorship	#5a Authors contribution	16
Roles and responsibilities: sponsor contact information	#5b N/A no sponsor	
Roles and responsibilities: sponsor and funder	#5c	16
Roles and responsibilities: committees	#5d N/A no committees	
Introduction		
Background and rationale	#6a	5, 6
Background and rationale: choice of comparators	#6b	5, 6
Objectives	#7 Primary and secondary	6

Trial design	#8		6
Methods: Participants, interventions, and outcomes			
Study setting	#9		6
Eligibility criteria	#10	Inclusion and exclusion criteria for participants.	6, 7
Interventions: description	#11a		8
Interventions: modifications	#11b		9, 10
Interventions: adherence	#11c	N/A	
Interventions: concomitant care	#11d	Prophylactic treatment after SBT and other usual treatments	8
Outcomes	#12	Primary, secondary and exploratory	12
Participant timeline	#13	See also figures 1 and 2	11, 12
Sample size	#14		12
Recruitment	#15	Screening and informed consent.	7, 8
Methods: Assignment of interventions (for controlled trials)			
Allocation: sequence generation	#16a		7
Allocation concealment mechanism	#16b		7
Allocation: implementation	#16c		7
Blinding (masking)	#17a		7
Blinding (masking): emergency unblinding	#17b		7
Methods: Data collection, management, and analysis			
Data collection plan	#18a		11
Data collection plan: retention	#18b		11
Data management	#19		14
Statistics: outcomes	#20a		13
Statistics: additional analyses	#20b		13

Statistics: analysis population and missing data	#20c)	13
--	------------------------	----

Methods: Monitoring

Data monitoring: formal committee	#21a	14
-----------------------------------	----------------------	----

Data monitoring: interim analysis	#21b	13
-----------------------------------	----------------------	----

Harms	#22	N/A both arms can be considered standard of care
-------	---------------------	--

Auditing	#23	N/A non insurance
----------	---------------------	-------------------

Ethics and dissemination

Research ethics approval	#24	14
--------------------------	---------------------	----

Protocol amendments	#25	Amendment for ultrasound 14
---------------------	---------------------	-----------------------------

Consent or assent	#26a	7
-------------------	----------------------	---

Consent or assent: ancillary studies	#26b	N/A
--------------------------------------	----------------------	-----

Confidentiality	#27	14, 16
-----------------	---------------------	--------

Declaration of interests	#28	16
--------------------------	---------------------	----

Data access	#29	16
-------------	---------------------	----

Ancillary and post trial care	#30	16
-------------------------------	---------------------	----

Dissemination policy: trial results	#31a	14
-------------------------------------	----------------------	----

Dissemination policy: authorship	#31b	16
----------------------------------	----------------------	----

Dissemination policy: reproducible research	#31c	16
---	----------------------	----

Appendices

Informed consent materials	#32	Informed Consent in English
----------------------------	---------------------	-----------------------------

Biological specimens	#33	N/A No biological samples
----------------------	---------------------	---------------------------

The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative Commons Attribution License CC-BY-NC. This checklist was completed on 08. November 2023 using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

